Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
NEW HAVEN, Conn., April 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of Margaret Garin, MD, MSCR, as Vice President of Clinical Development. Dr. Garin will be responsible for progressing the clinical development of Haduvio in chronic cough and brings unique and relevant experience from her previous lead role in clinical development at Bellus Health.
- Dr. Garin will be responsible for progressing the clinical development of Haduvio in chronic cough and brings unique and relevant experience from her previous lead role in clinical development at Bellus Health.
- Her background spans various stages of the clinical development process including both strategic and executional roles, as well as the science of cough.
- "I am happy to welcome Meg to our team," said David Clark, Chief Medical Officer of Trevi Therapeutics.
- I am thrilled to have the ability to continue my work in chronic cough by joining the Trevi team to further the development of Haduvio for these patients."